In a male (or post‑menopausal female) patient with ferritin of 174 µg/L, low serum iron, high total iron‑binding capacity, and transferrin saturation of 11 %, does this ferritin level exclude iron‑deficiency anemia and what is the appropriate management?

This Patient Has Iron Deficiency Despite a Ferritin of 174 µg/L

With a transferrin saturation of 11%, low serum iron, and high TIBC, this patient has functional iron deficiency that requires treatment, regardless of the ferritin level of 174 µg/L. The ferritin is elevated as an acute-phase reactant, masking the true iron-deficient state revealed by the transferrin saturation.

Diagnostic Interpretation

The key diagnostic finding here is the transferrin saturation of 11%, which is well below the 20% threshold that defines iron deficiency 1. This pattern—elevated ferritin with low transferrin saturation—represents functional iron deficiency, where inflammation prevents mobilization of iron from stores despite apparently adequate ferritin levels 2, 3.

Why Ferritin Alone Is Misleading Here

• Ferritin is an acute-phase reactant that becomes elevated in inflammatory conditions, chronic kidney disease, and other chronic diseases 1
• The AGA guidelines explicitly state that in patients with chronic inflammatory conditions, ferritin levels may not accurately reflect body iron stores, and ferritin is usually <100 µg/L in true iron deficiency with inflammation, but can be higher 2, 1
• Transferrin saturation <20% is the confirmatory test when ferritin is unreliable 1, 4
• At 11%, this patient's TSAT indicates severe functional iron deficiency

The Clinical Picture

The combination of:

• Low serum iron
• High TIBC (indicating the body is trying to capture more iron)
• TSAT of 11% (severely reduced)
• Ferritin 174 µg/L (likely elevated by inflammation)

This pattern is diagnostic of iron deficiency in the setting of inflammation or chronic disease 5, 6, 3.

Management Algorithm

Step 1: Identify the Underlying Cause

Look specifically for:

• Gastrointestinal blood loss: This patient needs bidirectional endoscopy (EGD and colonoscopy) if asymptomatic, as recommended for all men and postmenopausal women with IDA 1
• Chronic inflammatory conditions: IBD, chronic kidney disease, heart failure, cancer, autoimmune conditions
• Malabsorption: Celiac disease, atrophic gastritis, H. pylori infection, prior bariatric surgery
• Dietary insufficiency: Vegan/vegetarian diet
• Medications: NSAIDs, proton pump inhibitors
• For premenopausal women: menstrual blood loss

Step 2: Iron Repletion Strategy

The choice between oral and IV iron depends on the underlying condition:

Use Intravenous Iron as first-line if:

• Active inflammatory bowel disease with compromised absorption 2
• Chronic kidney disease 5
• Heart failure 4
• Cancer 4
• Ongoing blood loss not responding to oral iron 2
• Malabsorption (celiac disease, post-bariatric surgery) 4
• Oral iron intolerance 4

Use Oral Iron as first-line if:

• No chronic inflammatory condition
• No malabsorption
• No ongoing significant blood loss
• Patient can tolerate oral therapy

Oral iron dosing: Ferrous sulfate 325 mg daily or on alternate days 4

Step 3: Monitor Response

• Recheck hemoglobin, ferritin, and transferrin saturation in 4-8 weeks
• Goal: Normalize hemoglobin and achieve TSAT >20%
• If no response to oral iron, switch to IV iron 2

Critical Pitfalls to Avoid

1. Do not dismiss iron deficiency based on ferritin >45 µg/L alone when TSAT is low—this is the most common error 2, 1

2. Do not use ferritin cutoffs of <15 or <30 µg/L in inflammatory conditions—these have poor sensitivity and will miss most cases 1

3. Do not delay endoscopic evaluation in men or postmenopausal women—GI malignancy must be excluded even if another cause seems apparent 1

4. Do not use oral iron in active IBD with inflammation—absorption is compromised and IV iron is superior 2

5. Do not assume adequate iron stores based on ferritin alone in patients with CKD, heart failure, cancer, or other chronic inflammatory conditions 2, 5

The Evidence Hierarchy

The 2024 AGA Clinical Practice Update 2 and 2020 AGA Guidelines 1 provide the strongest guidance, emphasizing that transferrin saturation is the key diagnostic test when ferritin is unreliable due to inflammation. The threshold of TSAT <20% combined with clinical context defines iron deficiency requiring treatment, regardless of ferritin level. Recent research confirms that ferritin can be elevated even with bone marrow iron depletion in inflammatory states 7, 3, and that TSAT better predicts response to iron therapy in these patients 5.